The Medicines Patent Pool (MPP) has just opened a call for expression of interest (EoI) inviting MPP licensees already manufacturing dolutegravir-approved products to take up a licence for dolutegravir (DTG) adults UMICs. DTG is recommended by the World Health Organization (WHO) as part of the preferred first-line and second-line regimen for people living with HIV, including pregnant women and those of childbearing potential.

This call follows on from the signing of a new voluntary licensing agreement between ViiV Healthcare and MPP in November 2020 to enable greater access of DTG-based regimens in certain upper-middle-income countries (UMICs). This new licensing agreement includes Azerbaijan, Belarus, Kazakhstan and Malaysia.

The agreement allows sublicensees to manufacture and supply DTG-based products to Azerbaijan, Belarus, Kazakhstan and Malaysia. Please note that applicants must already have a signed sublicence with MPP on DTG and have dolutegravir-approved products.

Submission deadline: 18 December 2020

Access the full licence agreement

Access the EoI portal

For any questions regarding the EOI Portal or this application, please email